• Home
  • About
  • Science
  • Pipeline
  • Team
  • News
  • Contact
  • More
    • Home
    • About
    • Science
    • Pipeline
    • Team
    • News
    • Contact
  • Home
  • About
  • Science
  • Pipeline
  • Team
  • News
  • Contact

Halo Biosciences

Halo Biosciences Halo Biosciences Halo Biosciences

Transforming the treatment of 

inflammatory and fibrotic diseases

Halo Biosciences

Halo Biosciences Halo Biosciences Halo Biosciences

Transforming the treatment of 

inflammatory and fibrotic diseases

Our Mission

Halo is a clinical-stage biotechnology company creating first-in-class, disease-modifying therapies for the treatment of inflammatory and fibrotic diseases. Our first indication is pulmonary hypertension and interstitial lung disease.






About Halo

Our Science

The ECM in Disease

We are building a differentiated pipeline based on novel insights into how  extracellular matrix (ECM) dysregulation drives disease 


Our primary target is Hyaluronan (HA), a key component of the ECM


Alterations to HA is associated with a variety of conditions characterized by inflammation and fibrosis, including pulmonary hypertension, pulmonary fibrosis, and liver fibrosis

About Our Science

Our Pipeline

Novel target for inflammation and fibrosis

Our pipeline is focused on delivering first- and best-in-class hyaluronan remodeling agents that act on novel targets with a differentiated mechanism of action


Our lead indication is pulmonary hypertension and interstitial lung disease,  a set of progressive and fatal diseases characterized by inflammation, fibrosis, and vascular remodeling of the lung

Our Pipeline
Meet Our Team

Contact Us

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Halo Biosciences Inc

Palo Alto, California, United States

Copyright © 2023 Halo Biosciences - All Rights Reserved.